Therapeutic Options in Anti–Jo‐1 Antisynthetase Syndrome With Interstitial Lung Disease: Comment on the Article by Marie et al

Cavagna, Lorenzo; Caporali, Roberto

doi:10.1002/acr.22024

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the previously mentioned evidence it is clear that differential diagnosis is fundamental in distinguishing RA-ILD from different conditions that can be great mimickers such as ASS or infectious diseases. This process is fundamental in order to promptly start the appropriate treatment, with significant influence on patients' prognosis [20, 148]. …”

Section: Differential Diagnosismentioning

confidence: 99%

“…Mycophenolate mofetil should be considered as a potentially useful treatment, considering its additional action on fibroblasts, endothelial cells, and smooth muscle cells [151, 152]. Similarly to ASS [20, 148], good results have been obtained with cyclosporine [153–156]. Despite the previously mentioned lung toxicity, cases of MTX and LEF efficacy in RA-ILD have been reported [157].…”

Section: Ra-ild Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis

Cavagna

Monti

Grosso

et al. 2013

BioMed Research International

Self Cite

102

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a relevant extra-articular manifestation of rheumatoid arthritis (RA) that may occur either in early stages or as a complication of long-standing disease. RA related ILD (RA-ILD) significantly influences the quoad vitam prognosis of these patients. Several histopathological patterns of RA-ILD have been described: usual interstitial pneumonia (UIP) is the most frequent one, followed by nonspecific interstitial pneumonia (NSIP); other patterns are less commonly observed. Several factors have been associated with an increased risk of developing RA-ILD. The genetic background plays a fundamental but not sufficient role; smoking is an independent predictor of ILD, and a correlation with the presence of rheumatoid factor and anti-cyclic citrullinated peptide antibodies has also been reported. Moreover, both exnovo occurrence and progression of ILD have been related to drug therapies that are commonly prescribed in RA, such as methotrexate, leflunomide, anti-TNF alpha agents, and rituximab. A greater understanding of the disease process is necessary in order to improve the therapeutic approach to ILD and RA itself and to reduce the burden of this severe extra-articular manifestation.

show abstract

Section: Differential Diagnosismentioning

confidence: 99%